SCYNEXIS, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
SCYNEXIS, Inc. (SCYX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.26 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-10
- SCYNEXIS, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 8.26M shares, a 199.54% increase year-over-year.
- SCYNEXIS, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 66.00M shares, a 197.03% increase year-over-year.
- SCYNEXIS, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 21.57M shares, a 3.92% decline year-over-year.
- SCYNEXIS, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 2.76M shares, a 87.75% decline year-over-year.
- SCYNEXIS, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 21.46M shares, a 4.24% decline from fiscal 2024.
- SCYNEXIS, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 22.41M shares, a 11.95% decline from fiscal 2023.
- SCYNEXIS, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 25.45M shares, a 3.43% decline from fiscal 2022.
- SCYNEXIS, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 26.36M shares, a 147.89% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 8.26M shares 10-Q · filed 2026-08-10 | 8.26M shares 10-Q · filed 2026-08-10 | ||||||
| 2026-03-31 | 66.00M shares 10-Q · filed 2026-05-11 | |||||||
| 2025-12-31 | 21.46M shares 10-K · filed 2026-03-04 | |||||||
| 2025-09-30 | 21.57M shares 10-Q · filed 2025-11-05 | 21.57M shares 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | 2.76M shares 10-Q · filed 2026-08-10 | 22.05M shares 10-Q · filed 2025-08-13 | 2.76M shares 10-Q · filed 2026-08-10 | 22.05M shares 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | 22.22M shares 10-Q · filed 2026-05-11 | |||||||
| 2024-12-31 | 22.41M shares 10-K · filed 2026-03-04 | |||||||
| 2024-09-30 | 22.45M shares 10-Q · filed 2025-11-05 | 22.45M shares 10-Q · filed 2024-11-06 | 22.45M shares 10-Q · filed 2025-11-05 | 22.45M shares 10-Q · filed 2024-11-06 | ||||
| 2024-06-30 | 22.49M shares 10-Q · filed 2025-08-13 | 22.49M shares 10-Q · filed 2025-08-13 | ||||||
| 2024-03-31 | 26.50M shares 10-Q · filed 2025-05-15 | |||||||
| 2023-12-31 | 25.45M shares 10-K · filed 2025-03-12 | |||||||
| 2023-09-30 | 27.20M shares 10-Q · filed 2024-11-06 | 24.41M shares 10-Q · filed 2024-11-06 | ||||||
| 2023-06-30 | 24.42M shares 10-Q · filed 2024-08-08 | 24.42M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 27.33M shares 10-Q · filed 2024-05-08 | |||||||
| 2022-12-31 | 26.36M shares 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | 27.10M shares 10-Q · filed 2023-11-13 | 27.10M shares 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | 27.14M shares 10-Q · filed 2023-08-14 | 27.14M shares 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | 10.88M shares 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | 10.63M shares 10-K · filed 2023-03-31 | |||||||
| 2021-09-30 | 20.47M shares 10-Q · filed 2022-11-09 | 15.17M shares 10-Q · filed 2022-11-09 | ||||||
| 2021-06-30 | 15.13M shares 10-Q · filed 2022-08-15 | 15.13M shares 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | 15.11M shares 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | 22.60M shares 10-K · filed 2022-03-29 | |||||||
| 2020-09-30 | 6.59M shares 10-Q · filed 2021-11-10 | 7.74M shares 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | 9.33M shares 10-Q · filed 2021-08-16 | 9.33M shares 10-Q · filed 2021-08-16 | ||||||
| 2020-03-31 | 7.70M shares 10-Q · filed 2021-05-17 | 76.98M shares 10-Q · filed 2020-05-11 | ||||||
| 2019-12-31 | 8.05M shares 10-K · filed 2021-03-29 | 80.50M shares 10-K · filed 2020-03-11 | ||||||
| 2019-09-30 | 1.85M shares 10-Q · filed 2020-11-06 | 18.49M shares 10-Q · filed 2019-11-12 | 2.99M shares 10-Q · filed 2020-11-06 | 29.87M shares 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | 3.03M shares 10-Q · filed 2020-08-10 | 30.26M shares 10-Q · filed 2019-08-07 | 30.26M shares 10-Q · filed 2019-08-07 | |||||
| 2019-03-31 | 30.77M shares 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | 29.71M shares 10-K · filed 2020-03-11 | |||||||
| 2018-09-30 | 29.72M shares 10-Q · filed 2019-11-12 | 29.76M shares 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | 29.83M shares 10-Q · filed 2019-08-07 | 29.83M shares 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |